Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.850 -0.030 (-1.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
EDIT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Why Editas Medicine Stock Is Jumping Today
The gene-editing biotech company provided its Q3 update. 
Via The Motley Fool
Should You Scoop Up Shares of This Promising Biotech on the Dip?
This gene-editing specialist could still be an excellent long-term play. 
Via The Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
Analyst Ratings For Editas Medicine
Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the fo... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful
EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
What's Hot in the Stock Market?
We've got a look at Merck and Amazon and Warby Parker and more. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
Investors craving treats should look elsewhere this month. 
Via The Motley Fool
Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal
One of the leading CRISPR stock is under pressure on underwhelming data. 
Via Investor's Business Daily
EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down.
Today, investors in Editas Medicine and EDIT stock are pricing in some clinical trial results that are being viewed negatively by the market. 
Via InvestorPlace
52 Biggest Movers From Yesterday
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share... 
Via Benzinga
PreMarket Prep Stock Of The Day: Editas Medicine
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber... 
Via Benzinga
Why Shares of Editas Medicine Are Lower This Morning
Incomplete data is disappointing investors after a long wait. 
Via The Motley Fool
Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress
Editas is working on a treatment for a blindness-causing genetic disorder. 
Via Investor's Business Daily
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
'Fast Money Halftime Report' Picks For September 13
On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year. She sees more upside... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wells Fargo lowered the price target on General Motors Company (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: 
Via Benzinga
3 Red-Hot Healthcare Stocks to Buy in September
These businesses are firing on all cylinders. 
Via The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.